{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:16Z","timestamp":1792197256768,"version":"4.4.0"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2013,5,31]]},"DOI":"10.18632\/oncotarget.990","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T17:46:47Z","timestamp":1442425607000},"page":"715-728","source":"Crossref","is-referenced-by-count":98,"title":["Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations"],"prefix":"10.18632","volume":"4","author":[{"given":"Jonathan M.","family":"Gerber","sequence":"first","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Gucwa","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Esopi","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Gurel","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Haffner","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milada","family":"Vala","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Nelson","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Yegnasubramanian","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2013,5,6]]},"reference":[{"issue":"14","key":"1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Sawyers","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"2","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"7","key":"3","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"issue":"1","key":"4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Mahon","year":"2007","journal-title":"Blood"},{"issue":"1","key":"5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Holyoake","year":"2002","journal-title":"Blood"},{"issue":"3","key":"6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05606.x","article-title":"Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors","volume":"130","author":"Jones","year":"2005","journal-title":"British journal of haematology"},{"issue":"11","key":"7","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Holyoake","year":"2006","journal-title":"Blood"},{"issue":"12","key":"8","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Forman","year":"2003","journal-title":"Blood"},{"issue":"11","key":"9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Rousselot","year":"2010","journal-title":"The lancet oncology"},{"issue":"19","key":"10","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Radich","year":"2010","journal-title":"Blood"},{"issue":"8","key":"11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"Deininger","year":"2012","journal-title":"Nature reviews Cancer"},{"issue":"11","key":"12","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood.V81.11.2898.2898","article-title":"BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia","volume":"81","author":"Jones","year":"1993","journal-title":"Blood"},{"issue":"5","key":"13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0301-472X(02)00787-7","article-title":"Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction","volume":"30","author":"Raymakers","year":"2002","journal-title":"Experimental hematology"},{"issue":"6","key":"14","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Melo","year":"2003","journal-title":"Blood"},{"issue":"1","key":"15","first-page":"103","article-title":"Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes","volume":"2","author":"Ehrlich","year":"2003","journal-title":"Cancer biology & therapy"},{"issue":"4","key":"16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2141.2005.05596.x","article-title":"Normal and leukaemic stem cells","volume":"130","author":"Bonnet","year":"2005","journal-title":"British journal of haematology"},{"issue":"9","key":"17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3324\/haematol.11366","article-title":"Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity","volume":"92","author":"Eaves","year":"2007","journal-title":"Haematologica"},{"issue":"15","key":"18","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","article-title":"A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia","volume":"119","author":"Jones","year":"2012","journal-title":"Blood"},{"issue":"2","key":"19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1081\/DMR-120034001","article-title":"Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism","volume":"36","author":"Estey","year":"2004","journal-title":"Drug metabolism reviews"},{"issue":"1","key":"20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","article-title":"Characterization of chronic myeloid leukemia stem cells","volume":"86","author":"Jones","year":"2011","journal-title":"American journal of hematology"},{"issue":"1","key":"21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Lempicki","year":"2009","journal-title":"Nature protocols"},{"issue":"1","key":"22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gkn923","article-title":"Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists","volume":"37","author":"Lempicki","year":"2009","journal-title":"Nucleic acids research"},{"issue":"43","key":"23","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Mesirov","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0962280209351908","article-title":"Gene set enrichment analysis made simple","volume":"18","author":"Speed","year":"2009","journal-title":"Statistical methods in medical research"},{"issue":"169","key":"25","article-title":"DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases","volume":"5","author":"Yegnasubramanian","year":"2013","journal-title":"Science translational medicine"},{"issue":"2","key":"26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/08977199409010986","article-title":"Characterization of CD34+HLA-DR-CD38+ and CD34+HLA-DR-CD38- progenitor cells from human umbilical cord blood","volume":"10","author":"Boyd","year":"1994","journal-title":"Growth Factors"},{"issue":"1","key":"27","first-page":"25","article-title":"Gene ontology: tool for the unification of biology","volume":"25","author":"Matese","year":"2000","journal-title":"The Gene Ontology Consortium. Nature genetics"},{"issue":"Database issue","key":"28","first-page":"D109","article-title":"KEGG for integration and interpretation of large-scale molecular data sets","volume":"40","author":"Tanabe","year":"2012","journal-title":"Nucleic acids research"},{"issue":"1","key":"29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Goto","year":"2000","journal-title":"Nucleic acids research"},{"issue":"11","key":"30","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1073\/pnas.95.11.6331","article-title":"Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26\/dipeptidyl peptidase IV-mediated cleavage","volume":"95","author":"Nagai","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7044","key":"31","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/nature03703","article-title":"In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment","volume":"435","author":"Lin","year":"2005","journal-title":"Nature"},{"key":"32","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.2741\/2799","article-title":"DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes","volume":"13","author":"Holst","year":"2008","journal-title":"Frontiers in bioscience : a journal and virtual library"},{"issue":"145","key":"33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/scitranslmed.3004440","article-title":"Anti-CD25 immunotherapy: regulating the regulators","volume":"4","author":"Rose","year":"2012","journal-title":"Science translational medicine"},{"issue":"37","key":"34","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"Fioretos","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","article-title":"Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"8","key":"36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"van der Meer","year":"2012","journal-title":"Nature reviews Drug discovery"},{"issue":"3","key":"37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nature reviews Cancer"},{"issue":"3","key":"38","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1158\/0008-5472.CAN-09-2303","article-title":"Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells","volume":"70","author":"Wu","year":"2010","journal-title":"Cancer research"},{"issue":"5","key":"39","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/leu.2008.392","article-title":"The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence","volume":"23","author":"Brors","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"40","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.3109\/10428194.2012.696313","article-title":"Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation","volume":"53","author":"Skorski","year":"2012","journal-title":"Leukemia & lymphoma"},{"key":"41","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer","author":"de Bono","year":"2012","journal-title":"Investigational new drugs"},{"issue":"12","key":"42","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/bjc.2011.177","article-title":"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2\/1)","volume":"104","author":"O'Dwyer","year":"2011","journal-title":"British journal of cancer"},{"issue":"2","key":"43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Schwartz","year":"2012","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"4","key":"44","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2011.290","article-title":"Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease","volume":"20","author":"Pallone","year":"2012","journal-title":"Molecular therapy : the journal of the American Society of Gene Therapy"},{"issue":"4","key":"45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jb\/mvr016","article-title":"TGF-beta1-induced PI3K\/Akt\/NF-kappaB\/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts","volume":"149","author":"Zhao","year":"2011","journal-title":"Journal of biochemistry"},{"issue":"7281","key":"46","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Hirao","year":"2010","journal-title":"Nature"},{"issue":"7","key":"47","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.febslet.2007.02.048","article-title":"Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia","volume":"581","author":"Chantry","year":"2007","journal-title":"FEBS letters"},{"issue":"15","key":"48","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1073\/pnas.1633291100","article-title":"The two faces of transforming growth factor beta in carcinogenesis","volume":"100","author":"Wakefield","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"49","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrc1926","article-title":"Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer","volume":"6","author":"Moses","year":"2006","journal-title":"Nature reviews Cancer"},{"issue":"Part 3","key":"50","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1467-9868.00346","article-title":"A direct approach to false discovery rates","volume":"64","author":"Storey","year":"2002","journal-title":"J R Statist Soc B"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T04:48:01Z","timestamp":1589431681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,6]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5,31]]}},"alternative-id":["990","23651669"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.990","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,6]]}}}